DALLAS--(BUSINESS WIRE)--Peloton Therapeutics, Inc., a clinical-stage pharmaceutical company advancing first-in-class oral medicines for cancer and other serious conditions, announced today that it will be presenting at the 37th Annual J.P. Morgan Healthcare Conference. John A. Josey, Ph.D., Chief Executive Officer, will present at 3:30 p.m. PDT on Tuesday, January 8, 2019 at the Westin St. Francis in San Francisco, California.
About Peloton Therapeutics
Peloton Therapeutics, Inc. is a clinical-stage pharmaceutical company that is translating groundbreaking scientific insights into first-in-class oral medicines for patients with cancer and other serious or life-threatening conditions. The company’s lead development program is evaluating the only clinical-stage small-molecule inhibitor of hypoxia-inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of kidney cancer and a wide variety of other disorders. Peloton is also progressing several research programs by building upon its success in inhibiting HIF-2α, which was previously thought to be intractable using small molecules.
To learn more about Peloton Therapeutics, visit www.pelotontherapeutics.com.